1370 / 1601
ESTRO IG and Adaptive Course
Parikh Budapest 2018
No Grade 3 toxicity at
median 11.8 mo f/u
Expected 20-30% using
aggressive dose
regimen
No change in patient-
reported EORTC-qlq 30
QOL scores (
P =
0.29)
at 0, 6, and 12wks.
Phase I Results—Clinical Outcomes
0
10
20
30
40
50
60
70
80
0
6
12
Quality of Life Score
Time Since Completion
of Therapy (weeks)
Mean EORTC-30 QOL Score
Henke et al, ASTRO 2016